Free Trial
NASDAQ:RLYB

Rallybio (RLYB) Stock Price, News & Analysis

Rallybio logo
$0.73 -0.01 (-0.74%)
Closing price 04:00 PM Eastern
Extended Trading
$0.73 +0.00 (+0.27%)
As of 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Rallybio Stock (NASDAQ:RLYB)

Key Stats

Today's Range
$0.70
$0.77
50-Day Range
$0.63
$1.00
52-Week Range
$0.62
$3.46
Volume
31,786 shs
Average Volume
474,695 shs
Market Capitalization
$30.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.75
Consensus Rating
Moderate Buy

Company Overview

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Remove Ads

Rallybio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

RLYB MarketRank™: 

Rallybio scored higher than 50% of companies evaluated by MarketBeat, and ranked 574th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Rallybio has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Rallybio has only been the subject of 1 research reports in the past 90 days.

  • Read more about Rallybio's stock forecast and price target.
  • Earnings Growth

    Earnings for Rallybio are expected to grow in the coming year, from ($1.34) to ($1.09) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Rallybio is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Rallybio is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Rallybio has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Rallybio's valuation and earnings.
  • Percentage of Shares Shorted

    1.65% of the float of Rallybio has been sold short.
  • Short Interest Ratio / Days to Cover

    Rallybio has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in Rallybio has recently increased by 1.93%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Rallybio does not currently pay a dividend.

  • Dividend Growth

    Rallybio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.65% of the float of Rallybio has been sold short.
  • Short Interest Ratio / Days to Cover

    Rallybio has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in Rallybio has recently increased by 1.93%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Rallybio has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Rallybio this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for RLYB on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Rallybio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.40% of the stock of Rallybio is held by insiders.

  • Percentage Held by Institutions

    90.34% of the stock of Rallybio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Rallybio's insider trading history.
Receive RLYB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rallybio and its competitors with MarketBeat's FREE daily newsletter.

RLYB Stock News Headlines

Rallybio's (RLYB) "Buy" Rating Reiterated at HC Wainwright
Rallybio reports Q4 EPS (25c), consensus (30c)
Alert: DOGE goes live
Elon will most likely be at the helm of it all. And just days from now, could bring about the biggest economic transformation in American history. See, there's one particular part of Elon and Trump's plans that you need to pay special attention to right now.
JMP Securities Sticks to Their Buy Rating for Rallybio (RLYB)
See More Headlines

RLYB Stock Analysis - Frequently Asked Questions

Rallybio's stock was trading at $0.96 at the beginning of the year. Since then, RLYB stock has decreased by 24.3% and is now trading at $0.7270.
View the best growth stocks for 2025 here
.

Rallybio Co. (NASDAQ:RLYB) issued its earnings results on Thursday, March, 13th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.02. The business earned $0.04 million during the quarter, compared to analyst estimates of $0.15 million.

Rallybio (RLYB) raised $80 million in an initial public offering on Thursday, July 29th 2021. The company issued 5,750,000 shares at a price of $13.00-$15.00 per share.

Top institutional shareholders of Rallybio include Canaan Partners XI LLC (4.09%), Almitas Capital LLC (3.13%), Allostery Investments LP (1.94%) and Renaissance Technologies LLC (1.06%). Insiders that own company stock include Kush Parmar, Jonathan I Lieber and Jeffrey M Fryer.
View institutional ownership trends
.

Shares of RLYB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rallybio investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Plug Power (PLUG).

Company Calendar

Last Earnings
3/13/2025
Today
3/19/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RLYB
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.75
High Stock Price Target
$15.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+1,241.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-74,560,000.00
Pretax Margin
-10,794.48%

Debt

Sales & Book Value

Annual Sales
$636,000.00
Price / Cash Flow
N/A
Book Value
$2.81 per share
Price / Book
0.26

Miscellaneous

Free Float
38,418,000
Market Cap
$30.16 million
Optionable
Not Optionable
Beta
-1.45
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:RLYB) was last updated on 3/19/2025 by MarketBeat.com Staff
From Our Partners